CPG
ATNM icon

Cornerstone Planning Group’s Actinium Pharmaceuticals ATNM Stock Holding History

Cornerstone Planning Group’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-252
Closed -$474 – 1408
2024
Q3 		$474 Buy
+252
New +$996 ﹤0.01% 1098

Other funds holding ATNM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Los Angeles Capital Management
Los Angeles Capital Management Los Angeles, California $25.4B AUM 38.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Cornerstone Planning Group's ATNM Position: Q4 2024 in Review

Cornerstone Planning Group sold out of Actinium Pharmaceuticals (ATNM) in Q4 2024, closing a stake of 252 shares — an estimated $474 sold.

Cornerstone Planning Group first reported a position in ATNM in Q3 2024 and held it in 1 quarter. The position peaked at $474 in Q3 2024. 69 funds tracked by Wall St. Rank hold ATNM as of Q4 2024.

  • Cornerstone Planning Group reported no remaining Actinium Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Cornerstone Planning Group sold 252 Actinium Pharmaceuticals shares in Q4 2024, an estimated $474.
  • Cornerstone Planning Group first reported a position in Actinium Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Cornerstone Planning Group's Actinium Pharmaceuticals position peaked at $474 in Q3 2024.
  • 69 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q4 2024.

Based on Cornerstone Planning Group's 13F filing for Q4 2024, filed 29 Jan 2025.